Regarding cabergoline, resistance has been arbitrarily defined when there is no normalization of prolactin concentration and a reduction in tumor size of <50% at the maximum dose of 2.0 mg per week for 3 months, which is the dose recommended by the manufacturer as the most effective (8–10). The gene discussed is PRL; the disease is neoplasm.